John E Shively
Overview
Explore the profile of John E Shively including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
2610
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Development of Anti-CEA C2 Domain-Deleted Antibody (M5A∆C2) for the PET Imaging of Colorectal Cancer
Jitender J, Hong T, Sherman A, Wong P, Aniogo E, Kujawski M, et al.
Mol Imaging Biol
. 2025 Mar;
PMID: 40085171
Purpose: Recombinant antibody fragments represent a novel class of in vivo biological immunoPET imaging agents. This study developed a series of anti-carcinoembryonic antigen (CEA) C2 domain-deleted antibodies to evaluate their...
2.
Aniogo E, Kujawski M, Awuah D, Cha S, Espinosa R, Hui S, et al.
Front Immunol
. 2025 Jan;
15:1499471.
PMID: 39759518
Introduction: Although CAR-T cell therapy has limited efficacy against solid tumors, it has been hypothesized that prior treatment with Image-Guided Radiation Therapy (IGRT) would increase CAR-T cell tumor infiltration, leading...
3.
Najjar S, Shively J
Eur J Clin Invest
. 2024 Dec;
54 Suppl 2:e14338.
PMID: 39674882
This review focuses on a special aspect of hepatic lipid storage and inflammation that occurs during nutritional excess in obesity. Mounting evidence supports that prolonged excess fatty acid (FA) uptake...
4.
Dery K, Najjar S, Beauchemin N, Shively J, Kupiec-Weglinski J
Eur J Clin Invest
. 2024 Dec;
54 Suppl 2:e14350.
PMID: 39674874
Background: Alternative splicing is a fundamental mechanism in the post-transcriptional regulation of genes. The multifunctional transmembrane glycoprotein receptor carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) undergoes extensive alternative splicing to...
5.
Fleckenstein J, Najjar S, Zimmermann W, Hauck C, Nguyen Q, Mejias-Luque R, et al.
Eur J Clin Invest
. 2024 Dec;
54 Suppl 2:e14355.
PMID: 39674873
No abstract available.
6.
Kuznetsov M, Adhikarla V, Caserta E, Wang X, Shively J, Pichiorri F, et al.
Cancer Res Commun
. 2024 Oct;
4(11):2955-2967.
PMID: 39466073
Mathematical modeling yields general principles for optimization of TRT in mouse models of multiple myeloma that can be extrapolated to other cancer models and clinical settings.
7.
Zain J, Tsai N, Palmer J, Simpson J, Adhikarla V, Bading J, et al.
Blood Adv
. 2024 Jun;
8(18):4812-4822.
PMID: 38838232
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis with current treatments. High-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is used as a consolidation strategy after achieving clinical remission...
8.
Kuznetsov M, Adhikarla V, Caserta E, Wang X, Shively J, Pichiorri F, et al.
bioRxiv
. 2024 Jun;
PMID: 38826403
Targeted radionuclide therapy is based on injections of cancer-specific molecules conjugated with radioactive nuclides. Despite the specificity of this treatment, it is not devoid of side-effects limiting its use and...
9.
Adhikarla V, Awuah D, Caserta E, Minnix M, Kuznetsov M, Krishnan A, et al.
Front Immunol
. 2024 May;
15:1358478.
PMID: 38698840
Introduction: Cancer combination treatments involving immunotherapies with targeted radiation therapy are at the forefront of treating cancers. However, dosing and scheduling of these therapies pose a challenge. Mathematical models provide...
10.
Centonze M, Fiori V, Kujawski M, Li L, Wong P, Williams L, et al.
PLoS One
. 2024 Feb;
19(2):e0295345.
PMID: 38346003
Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1), a homotypic cell adhesion molecule glycoprotein with apical expression on normal epithelial cells and activated lymphocytes, is overexpressed on many tumors and acts as...